AbbVie (ABBV) reported promising results from the Phase 2 IMGN853-0420 trial evaluating mirvetuximab soravtansine-gynx (ELAHERE) in combination with carboplatin, followed by mirvetuximab soravtansine monotherapy. In patients with platinum-sensitive ovarian cancer (PSOC) who had =50% folate receptor alpha (FRa) expression, the regimen achieved an objective response rate of 62.7%. Importantly, the safety profile remained consistent with prior findings, underscoring the tolerability of this antibody-drug conjugate approach.
These findings highlight the potential of mirvetuximab soravtansine across the ovarian cancer treatment continuum, particularly in FRa-positive populations where targeted therapy can make a meaningful impact. The data presentation is scheduled during the Rapid-Fire Oral III: Translational and ADC session on Sunday, April 12 at 12:32 PM ET, offering an important opportunity to discuss how this therapy could reshape treatment strategies for platinum-sensitive ovarian cancer.
ABBV closed at $207.94, down $4.46 or 2.10% on April 10. After hours, the stock showed a slight recovery, trading at $208.20, up $0.26 or 0.13%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.